March 13th, 2020
MaaT Pharma – Information COVID-19
In the context of the COVID-19 infection pandemic, MaaT Pharma has taken corresponding precautionary measures regarding the collection of stools that go into the production of our medicines. For all patients treated or in treatment, our products were produced well before the onset of the COVID-19 epidemic.
A few weeks ago, we launched a new stool collection and production campaign. In order to ensure the safety of these new products, we implemented strict measures regarding the monitoring of donors including the identification of any risk of these donors to be COVID-19 carriers. This new campaign has concluded today.
As part of the usual collection process, donors are monitored weekly by qualified personnel that always includes a physician; this monitoring has meanwhile been reinforced, and will be repeated in the coming weeks.
Moreover, MaaT Pharma is closely collaborating with our (French) national agency, the ANSM (National Agency for the Safety of Medicines and Health Products), as well as with the other relevant European health authorities to implement any and all provisions to ensure the safety of our products as the pandemic evolves.
MaaT Pharma is committed to regularly communicating about this topic with the greatest transparency.
Hervé Affagard, CEO
